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Background: Human immuno-deficiency virus (HIV) infection and tuberculosis are common and often co-occurring
conditions in sub-Saharan Africa (SSA). We investigated the effects of HIV testing and HIV status on the outcomes of
tuberculosis treatment in a major diagnosis and treatment centre in Yaounde, Cameroon.
Methods: Participants were 1647 adults with tuberculosis registered at the Yaounde Jamot’s Hospital between
January and December 2009. Multinomial logistic regression models were used to relate HIV testing and HIV status
to the outcomes of tuberculosis treatment during follow-up, with adjustment for potential covariates.
Results: Mean age of participants was 35.5 years (standard deviation: 13.2) and 938 (57%) were men. Clinical forms
of tuberculosis were: smear-positive (73.8%), smear-negative (9.4%) and extra-pulmonary (16.8%). Outcomes of
tuberculosis treatment were: cure/completion (68.1%), failure (0.4%), default (20.1%), death (5.2%) and transfer
(6.3%). Using cure/completion as reference, not testing for HIV was associated with adjusted odds ratio of 2.30 (95%
confidence interval: 1.65-3.21), 2.26 (1.29-3.97) and 2.69 (1.62-4.46) for the risk of failure/default, death and transfer
respectively. The equivalents for a positive test among those tested (1419 participants) were 1.19 (0.88-1.59), 6.35
(3.53-11.45) and 1.14 (0.69-1.86).
Conclusions: Non-consent for HIV testing in this setting is associated with all unfavourable outcomes of
tuberculosis treatment. However been tested positive was the strongest predictor of fatal outcome. Efforts are
needed both to improve acceptance of HIV testing among patients with tuberculosis and optimise the care of
those tested positive.
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Human immunodeficiency virus (HIV) infection and tu-
berculosis are major health problems in sub-Saharan Af-
rica (SSA). In 2009 alone, 35% of the global 9.4 millions
declared cases of tuberculosis (TB) were registered in
Africa. In that same year, the rate of TB/HIV co-
infection at the global level was 11–13%, but was as high
as 80% in Africa [1]. HIV infection favours the* Correspondence: pefura2002@yahoo.fr
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distribution, and reproduction in any mediumreactivation and progression of latent Mycobacterium tu-
berculosis infection to overt tuberculosis infection, and
Mycobacterium tuberculosis favours the replication of
HIV and precipitates the natural course of the infection
toward advanced stage or severe immune-depression
[2,3]. Once tuberculosis becomes clinically manifest, co-
infection with HIV is generally associated with poor
outcome in SSA [4]. TB/HIV co-infection has been well-
documented in SSA with regard to smear-positive pul-
monary tuberculosis [5-8]. The changing pattern with
time has been described in places as well. In Cameroon
for instance, the prevalence of HIV infection among
those with smear-positive pulmonary tuberculosisntral Ltd. This is an Open Access article distributed under the terms of the
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[5,9]. However, little is known about the prevalence of
HIV in other clinical form of tuberculosis, as well as
effects of HIV on the broad categories of outcomes of
care for tuberculosis.
The current study has assessed the prevalence of HIV
infection among African adults with tuberculosis, re-
gardless of the clinical form, and quantified the effects of
failure to test for HIV, and HIV status on the outcome
of tuberculosis treatment in a major diagnosis and treat-
ment centre in Cameroon.
Methods
Study setting
The study was conducted in the pneumology service of
Yaounde Jamot’s Hospital (YJH). The YJH serves a refer-
ral centre for tuberculosis and respiratory diseases for
the capital city of Cameroon (Yaounde) and surrounding
areas as described in detail elsewhere [10]. It is one of
the major centres for diagnosis and treatment of tuber-
culosis (CDT) in Cameroon, and YJH also host an
approved treatment centre for people living with HIV in-
fection. From year 2006 to 2011, about 1600 to 1800
patients with tuberculosis were diagnosed and treated
on an annual basis in this CDT. In the year 2009, up to
11% of all cases of tuberculosis diagnosed in the country
were managed at the YJH. Patients received at the CDT
during January to December 2009 were considered for
inclusion in the study. The study was approved by the
institutional review board of the YJH.
Definition and classification of tuberculosis cases
Patients who receive care at the CDT of YJH are con-
secutively registered as they are started on treatment.
For those with a past exposure to antituberculosis treat-
ment, the approach is nearly similar. Patients who report
back to the centre with active tuberculosis and who have
been treated in the past for at least one month are regis-
tered again with a new number and started on a standar-
dised re-treatment regimen. The following international
definitions are applied: [2,3,9] 1) smear-positive pulmon-
ary tuberculosis (PTB+) - acid-fast bacilli (AFB) found in
at least two sputum specimens; 2) smear-negative pul-
monary tuberculosis (PTB-) – persisting negativity on
three sputum examinations after ten-day course of non-
specific antibiotic treatment in a patient with
tuberculosis-like clinical and radiological signs, and in
the absence of any obvious cause; 3) extra-pulmonary
tuberculosis (EPTB) – tuberculosis involving organs
other than the lungs. Patients with past exposure to anti-
tuberculosis treatment are usually all smear-positive and
are further classified as “relapse” (i.e. reoccurrence of the
disease following a successful antituberculosis treatment
course), “failure” (i.e. positive smear after five months ofantituberculosis treatment) and “treatment after default”
(i.e. starting antituberculosis treatment again after two
consecutive months of interruption). A “new case” is a
patient with tuberculosis who has never been exposed to
antituberculosis treatment for more than one month in
the past. “Other cases of tuberculosis” referred to
patients who cannot fit in one of the categories
described above.Detection and management of HIV infection
At the CDT of the YJH, all patients with tuberculosis are
screened for HIV infection free of charge after informed
consent has been obtained from the patient or relative
for dependant patients. This includes detection of anti-
HIV 1 and anti-HIV 2 antibodies in the serum with the
use of two rapid tests: DetermineW HIV ½(Abbot labora-
tories, Tokyo, Japan) and ImmunocombW II HIV 1 and 2
Bispot (Organics, Courbevoie, France). A patient is clas-
sified as HIV positive when the two tests are positive.
For discordant tests, a confirmatory western blot test
(New Lav Blot, Sanofi diagnostics-Pasteur) is conducted.
All HIV-positive patients are started on prophylaxis with
cotrimoxazole and those with CD4 count <200/mm3 are
started on highly active antiretroviral therapy free of
charge. Initial antiretroviral regimens are the combina-
tions lamivudine-zidovudine-efavirenz or lamivudine-
stavudine-efavirenz.Tuberculosis treatment
Tuberculosis treatment at the CDT is made according to
the guidelines of the Cameroon National Programme
Against Tuberculosis (NPAT) and the WHO recommen-
dations [11,12]. Patients are either admitted during the
intensive phase of antituberculosis treatment, or treated
as outpatient. Antituberculosis drugs are dispensed free
of charge to all patients. Treatment regimens used are
standard regimens of category I for new patients and of
category II for re-treatment cases. New cases are treated
with a regimen that includes an intensive phase of two
months duration with rifampicin (R), isoniazid (H), eth-
ambutol (E) and pyrazinamide (Z), followed by a 4-
month continuation phase with rifampicin and isoniazid
(2RHEZ/4RH). During re-treatment, category I medica-
tions (R, H, E, Z) are completed with streptomycin (S).
Therefore, re-treatment cases are treated with RHEZS
for two months, followed by one month on RHEZ and
five months on RHE (2RHEZS/1RHEZ/5RHE). During
the intensive phase, adherence is directly monitored by
the healthcare team for patients admitted, and during
weekly drug collection in those treated as outpatients.
The continuation phase is conducted on the outpatient
basis and adherence assessed during monthly drugs col-
lection visits.
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During antituberculosis treatment, PTB+ patients are
re-examined for AFB at the end of month 2, 5 and 6 for
new cases, and at the end of month 3, 5 and 8 in case of
re-treatment. PTB- and patients with EPTB are moni-
tored clinically and/or radiologically at the same fre-
quency. At the end of the treatment, patients are ranked
into mutually exclusive categories [13] as: 1) cured – pa-
tient with negative smear at the last month of treatment
and at least one of the preceding; 2) treatment com-
pleted – patient who has completed the treatment and
for whom the smear result at the end of the last month
is not available; 3) failure – patient with positive smear
at the 5th month or later during treatment; 4) death –
death from any cause during treatment; 5) defaulter –
patient who’s treatment has been interrupted for at least
two consecutive months; 6) transfer – patient trans-
ferred to complete his treatment in another centre and
who’s treatment outcome is unknown.
Data collection
This was a retrospective cohort study among TB
patients aged ≥ 15 years. Tuberculosis treatment regis-
ters and antituberculosis treatment forms of the YJH’s
CDT served as basis for data collection for the study.
Data were collected on age, sex, residence (urban vs.
rural), history of exposure to antituberculosis treatment,
localisation of tuberculosis infection, status for HIV in-
fection, CD4 lymphocyte count (in those with HIV in-
fection) and outcome of antituberculosis treatment.
Cured and antituberculosis treatment completion were
considered as favourable outcome (successful treatment)
while death, default and failure were considered as un-
favourable outcome [14].
Statistical methods
Data analysis used SPSSW v.12.0.1 for WindowsW (SPSS
Inc., Chicago, USA) and SAS/STATW v 9.1 for windows
(SAS Institute Inc., Cary, NC, USA). Results are presented
as count (proportions), means (standard deviation, SD) or
median (interquartile range, IQR). Group comparisons
used chi square of Fisher exact test for qualitative vari-
ables, and Student t-test or Mann-Whitney U test for
quantitative variables. Multinomial Logistic regression
models were used to investigate the effects of HIV testing
and HIV status on the outcomes of tuberculosis in sex
and age adjusted analysis, and after further adjustment for
other potential confounders. A p-value < 0.05 was used to
characterise statistically significant results.
Results
Study population
During the year 2009, 1647 patients were screened and
treated for tuberculosis at the Yaounde Jamot Hospital’sCentre for Diagnosis and Treatment. They were aged
33 years (interquartile range: 25-43 years) and 938 (57%)
were men. Clinical forms of tuberculosis were: 1216
(73.8%) for PTB+, 155 (9.4%) for PTB- and 276 (16.8%)
for PTB (Table 1).
Outcomes of TB
In all, 272 (16.5%) patients were cured and 849 (51.5%)
successfully completed the treatment, giving and overall
treatment success rate of 68.1%. Other outcomes of care
were failure (0.4%), death (5.2%), default (20.1%) and
transfer (6.1%). Characteristics of participants according
to the outcomes of care are described in Table 1, show-
ing some significant differences in the distribution by
residence (urban vs. rural) and clinical forms of
tuberculosis.
HIV testing and status
A total 1419 (86.2%) patients were tested for HIV, and
497 (35%) were positive for HIV, all for HIV-1 subtype.
Of those tested positive, 229 (46.1%) received antiretro-
viral therapy. Compared with those who did not test,
patients who tested for HIV were borderline younger
(35.3 vs. 37.0 years, p = 0.06), included more women
(44.6% vs. 33.3%, p = 0.001), and more individuals with
smear positive tuberculosis than with smear negative or
extra-pulmonary tuberculosis (75.8%, 8%, 16.2% vs.
61.8%, 18% and 20.2%, p < 0.001). Among participants
tested for HIV, patients with positive status as compared
with the negative ones were older (36 vs. 30 years,
p < 0.001), included more women (57.1% vs. 37.3%,
p < 0.001), included fewer patients with smear positive
than with smear negative and extra-pulmonary tubercu-
losis (67.6%, 10.3%, 22.1% vs. 80.1%, 6.8%, 13%,
p < 0.001). The distribution of participants according to
whether they were tested for HIV and/or whether such
test was positive varied significantly across outcome of
care for tuberculosis (Table 1).
Determinants of the outcomes of care
In sex and age adjusted multinomial logistic regression
analysis, and using the combined outcome of cure/
treatment completed (treatment success) as the refer-
ence, not testing for HIV was positively and significantly
associated with treatment default/failure, deaths and
transferred-out (Table 2). The range of effect was similar
from these 3 broad outcomes. Among those tested for
HIV, a positive status was associated with an odds ratio
(95% confidence interval) of 6.40 (3.57-11.46) for mortal-
ity, but had no effect on other outcomes (Table 2). Simi-
lar range of effect was observed when participants with
unknown status for HIV were compared with those with
negative status [6.49 (3.26-12.93)]. In sex and age
adjusted analysis, age was associated with mortality,
Table 1 Characteristics of patients with tuberculosis according to the treatment outcome at the Jamot Hospital in 2009
Characteristics Categories Total Outcomes of tuberculosis treatment
Cured/Completed* Failure Deaths Defaulted Transferred P-value
N(%) 1647 1121 (68.1) 6 (0.4) 86 (5.2) 331 (20.1) 103 (6.3)
Age, years, n(%)
≤33 854 (51.9) 609 (71.3) 2 (0.2) 24 (2.8) 172 (20.1) 47 (5.5) <0.001
>33 793 (48.1) 512 (64.6) 4 (0.5) 62 (7.8) 159 (20.1) 56 (7.1)
Mean (SD) 35.5 (13.2) 35.3 (12.9) 37.3 (13.7) 43.9 (14) 35.7 (13.3) 37.1 (13.9) <0.001
Men, n (%) 938 (57) 635 (67.7) 4 (0.4) 50 (5.3) 194 (20.7) 55 (5.9) 0.467
Urban residence, n (%) 1390/1622 (85.7) 968 (69.6) 5 (0.4) 72 (5.2) 278 (20) 67 (4.8) <0.001
Clinical forms, n (%)
PTB+ 1216 (73.8) 845 (69.5) 6 (0.5) 56 (4.6) 239 (19.7) 70 (5.7) <0.001
PTB- 155 (9.4) 86 (55.5) 0 (0) 16 (10.3) 42 (27.1) 11 (7.1)
EPTB 276 (16.8) 190 (68.8) 0 (0) 14 (5.1) 50 (3.7) 22 (8.0)
Type of patient, n (%)
New cases 1505 (91.4) 1026 (68.2) 5 (0.3) 81(5.4) 295 (19.6) 98 (6.5) 0.27
Relapse 119 (7.2) 81(68.1) 1 (0.8) 5 (4.2) 28 (23.5) 4 (3.4)
Failure 3 (0.2) 2 (66.7) 0 (0) 0 (0) 0 (0) 1 (33.3)
Defaulters 20 (1.2) 12 (60) 0 (0) 0 (0) 8 (40) 0 (0)
HIV serology, n (%)
Not done 228 (13.8) 113 (49.6) 2 (0.9) 20 (8.8) 69 (30.3) 24 (10.5) <0.001
Negative 922/1419 (65) 685 (74.3) 4 (0.4) 17 (1.8) 166 (18) 50 (5.4) <0.001
Positive 497/1419 (35) 323 (65.0) 0 (0) 49 (9.8) 96 (19.3) 29 (5.8)
SD, standard deviation; EPTB, extra-pulmonary tuberculosis ; PTB+, smear positive pulmonary tuberculosis ; PTB-, smear negative pulmonary tuberculosis; cured +
completed = therapeutic success.
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with death and treatment default/failure (Table 2).
In multivariable analysis, with further adjustment for
residence and clinical form of tuberculosis, associations
of HIV testing and HIV status with the outcome of treat-
ment were largely similar to those observed in age and
sex adjusted analysis, with only marginal attenuation of
the effect sizes (Table 3). However, the global effect of
clinical form of tuberculosis on the outcome of antitu-
berculosis treatment was no longer significant (p-value =
0.140 for the likelihood ratio test).
Effects of HIV severity on the outcomes of tuberculosis
treatment
A subgroup of HIV positive patient (278) also had CD4
count data available. Figure 1 show the distribution of
outcomes of tuberculosis care according to the stage of
immune-depression in this subgroup. Mortality rate
increased with decreasing CD4 count (CD4 count < 200/
mm3) while treatment success was better in those with
higher CD4 count (p = 0.03, Figure 1).
Discussion
Our study from this historical diagnosis and treatment
centre for tuberculosis in Cameroon has revealed thefollowing major findings: 1) In spite of successive effort
and several incentive, about one in eight patients still
fails to get screen for HIV during active tuberculosis. 2)
Among those tested, about a third is positive for HIV,
with women being disproportionately affected. 3) Not
testing for HIV or been tested positive are associated
with similar excess mortality, and furthermore, not test-
ing is associated with all poor outcomes of tuberculosis
treatment.
The co-occurrence of HIV infection and tuberculosis
is a well-known fact in Africa. Indeed, the re-emergence
of tuberculosis in SSA over the last two decades largely
mirrored the explosion of HIV epidemic in this region
[4,15]. Most recent studies from Africa suggest that rates
of TB/HIV co-infection range from 16% to about 80%
[6,7,16-20]. In Asia where tuberculosis is also common,
co-occurrence with HIV is found in less than 38% of
patients [1,21,22]. In Cameroon, the prevalence of TB/
HIV co-infection was 16.6% in 1997 [9], and further
increased to 29.3% in 2007 [5] among patients with
smear positive pulmonary tuberculosis, at the Yaounde
Jamot’s Hospital. This shift mirrors the rising trend of
HIV infection at the community level in Yaounde, with
prevalence rates increasing from 3% in 1994 [23] to 5.1%
in 2007 [24].
Table 2 Sex and age adjusted predictors of the tuberculosis treatment outcome, odds ratio and 95% confidence
interval
Cured/completed Default/failure Deaths Tranferred LR test (p-value)
Age, per year 1 (reference) 1.01 (1.00–1.02) 1.05 (1.03-1.06) 1.02 (1.00–1.03) <0.001
Sex, men vs. women 1 (reference) 1.07 (0.83–1.37) 0.91 (0.58-1.43) 0.83 (0.56–1.26) 0.717
Residence, urban vs. rural 1 (reference) 1.16 (0.81–1.66) 1.03 (0.55-1.94) 3.56 (2.26–5.62) <0.001
Clinical forms 0.032
PTB+ 1 (reference) 1 (reference) 1 (reference) 1 (reference)
EPTB 1 (reference) 1.11 (0.79–1.56) 1.00 (0.54–1.86) 0.74 (0.45–1.24)
PTB- 1 (reference) 1.83 (1.13–2.97) 2.42 (1.12–5.25) 1.09 (0.51–2.36)
Type of patient, new vs retreatment 1 (reference) 0.76 (0.51–1.14) 1.59 (0.63–4.06) 1.85 (0.74–4.67) 0.13
HIV serology <0.001
Negative 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Positive 1 (reference) 1.19 (0.89–1.59) 6.37 (3.55–11.41) 1.14 (0.70–1.86)
Not done 1 (reference) 2.51 (1.78–3.53) 6.49 (3.26–12.93) 2.87 (1.69–4.86)
HIV test, not done vs. done 1 (reference) 2.37 (1.70–3.28) 2.48 (1.43–4.31) 2.79 (1.69–4.60) <0.001
HIV serology*, Positive vs Negative 1 (reference) 1.19 (0.89–1.60) 6.40 (3.57–11.46) 1.13 (0.69–1.85) <0.001
PTB+, smear positive pulmonary tuberculosis ; EPTB, extra-pulmonary tuberculosis ; PTB-, smear negative pulmonary tuberculosis; LR, likelihood ratio ; *only in the
subgroup of participants with test done.
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pulmonary tuberculosis has been described elsewhere
[6,25,26]. Our findings therefore are largely in agreement
with published literature. Similarly, patients with SPTB-
were more likely to be HIV positive than those with
SPTB+. Unlike patients with tuberculosis and without
HIV, those with HIV are likely to have lung lesions without
cavitations [4,27], and accordingly negative smear [28].
We found that not testing for HIV or been tested posi-
tive were associated with similar range of risks for all-
cause mortality. This in some ways reflects the similarityTable 3 Multivariable adjusted predictors of the tuberculosis
interval
Cured/completed Default
Age, per year 1 (reference) 1.00 (0.9
Sex, men vs. women 1 (reference) 0.98 (0.7
Residence, urban vs. rural 1 (reference) 1.21 (0.8
Clinical forms
PTB+ 1 (reference) 1 (ref
EPTB 1 (reference) 1.21 (0.8
PTB- 1 (reference) 1.86 (1.1
Type of patient, new vs retreatment 1 (reference) 0.73 (0.4
HIV serology
Negative 1 (reference) 1 (ref
Positive 1 (reference) 1.19 (0.8
Not done 1 (reference) 2.44 (1.7
HIV test, not done vs. done 1 (reference) 2.30 (1.6
HIV serology*, Positive vs Negative 1 (reference) 1.19 (0.8
PTB+, smear positive pulmonary tuberculosis ; EPTB, extra-pulmonary tuberculosis ;
subgroup of participants with the test done.of profile between patients not tested and those tested
positive, and may further suggest that a consistent num-
ber of those not tested would have been HIV positive
individuals, and perhaps with advanced stage of the dis-
ease. Furthermore, those patients who were not tested
for HIV were likely those who will default or who will
be transferred-out which is also full of significance. One
explanation would be that failure to get tested for HIV
in this setting is a simple and reliable indicator of future
poor adherence to antituberculosis treatment. Another
explanation could be that, non-consent for HIV testtreatment outcome, odds ratio and 95% confidence
/failure Deaths Tranferred LR test (p-value)
9–1.02) 1.04 (1.03-1.06) 1.01 (0.99-1.02) <0.001
6–1.27) 0.89 (0.56-1.41) 0.69 (0.45-1.05) 0.372
4–1.74) 1.10 (0.58-2.01) 3.81 (2.39-6.06) <0.001
0.140
erence) 1 (reference) 1 (reference)
5–1.73) 1.08 (0.58–2.02) 0.82 (0.48–1.40)
3–3.01) 2.08 (0.94–4.60) 1.18 (0.53–2.60)
8–1.11) 1.43 (0.56–3.68) 1.64 (0.64–4.20) 0.20
<0.001
erence) 1 (reference) 1 (reference)
9–1.59) 6.43 (3.57–11.57) 1.13 (0.95–1.85)
3–3.45) 6.09 (3.02–12.28) 2.76 (1.62–4.72)
5–3.21) 2.26 (1.29–3.97) 2.69 (1.62–4.46) <0.001
8–1.59) 6.35 (3.53–11.45) 1.14 (0.69–1.86) <0.001
PTB-, smear negative pulmonary tuberculosis; LR, likelihood ratio; *only in the
Figure 1 CD4 count and outcome of tuberculosis treatment among HIV positive patients. Therapeutic success, Death, Defaulted,
Transferred.
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tient, with renewed invitations to the patient to accept
the test. Under such a pressure, patients would either
abandon the treatment or request for their discharge or
transfer to another centre.
This study has some limitations. Among the subgroup
of patients tested positive for HIV, not everyone had
CD4 count, and therefore we were unable to fully ac-
count for the possible effect of advanced stage of HIV
infection on the outcome of care for tuberculosis. We’ve
got no suggestion that missing CD4 count would occur
in a differential way to affect the validity of our findings.
That no systematic effort was in place to trace patients
who dropped out during the year of the study has prob-
ably introduced some biases in our ranking of patients
according to the outcome of care. For instance, some
patients who died in-between antituberculosis treatment
drug collection visits would have been inappropriately
classified as drop-out. However, the effects of misclassifi-
cation if any would need to be very important to invali-
date our findings.
Our study also has major strengths. These include
our large sample size, including the totality of adults
patients followed at the CDT during the year of the
study. The choice of analytic methods has also allowed
us to examine the effects of HIV testing and HIV
status on the broad range of outcome of tuberculosis
treatment, which is what many previous investigators
have not done.Conclusions
HIV infection is frequent among patients with active tu-
berculosis in this setting and disproportionately affects
women. Both not testing for HIV and been tested posi-
tive confer a high risk of mortality in our patients with
tuberculosis. In addition, not testing for tuberculosis is
associated with poor outcomes of tuberculosis. Efforts
are needed to improve the acceptance of HIV testing
among patients with tuberculosis and reduce mortality
risk among those tested positive in our context.
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